Lumida
/CTMX
⌘K
CytomX Therapeutics Inc

CytomX Therapeutics Inc

CTMX
$3.29USD-1.79%-0.06 today

MARKET CAP

716.9M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$2
$8

AI Summary

Stalk
Buy NowMedium

CTMX is showing early Stage 1 repair after the mid-June low, confirmed by a Bullish Pivot Point pattern and stacked short-term EMAs; medium-term bias shifts bullish, and execution on holds above the EMA9/20 support is warranted.

  • ORR of 28% and median PFS of 7.1 months in colorectal cancer
  • $346.7M cash as of Q1 2026 underpins R&D runway through 2027
  • Q1 2026 revenue dropped 80% to $10.3M from $50.9M YoY
Full analysis →

Buying

5

institutions

Selling

8

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
BI

Blackrock, Inc.

Q2 2026

BUY17.56 M65.85 M+12.33 M+168.0%0.00%
PA

Perceptive Advisors LLC

Q2 2026

SELL10.44 M39.15 M+-9.76 M-58.8%0.59%
PA

Point72 Asset Management, L.P.

Q2 2026

SELL7.81 M29.29 M+-64.36 K-20.9%0.03%
EP

Eversept Partners, LP

Q2 2026

BUY3.56 M13.34 M+369.98 K-10.9%0.69%
AC

Adar1 Capital Management, LLC

Q2 2026

SELL3.37 M12.62 M+-45.07 K-21.3%0.58%
CA

Citadel Advisors LLC

Q2 2026

SELL3.33 M12.49 M+-2.57 M-55.0%0.00%
WP

Woodline Partners LP

Q2 2026

SELL2.04 M7.65 M+-1.96 M-59.3%0.02%
MM

Millennium Management LLC

Q2 2026

SELL1.69 M6.32 M+-1.97 M-63.3%0.00%
JH

Janus Henderson Group Plc

Q1 2026

BUYNEW93.40 K439.45 K+93.40 K+0.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY109.41 K409.20 K+78.67 K+201.8%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUYNEW42.01 K157.55 K+42.01 K+0.0%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

SELL0.000.00+-730.84 K-100.0%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL0.000.00+-269.20 K-100.0%0.00%